MX2024008571A - Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados. - Google Patents
Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados.Info
- Publication number
- MX2024008571A MX2024008571A MX2024008571A MX2024008571A MX2024008571A MX 2024008571 A MX2024008571 A MX 2024008571A MX 2024008571 A MX2024008571 A MX 2024008571A MX 2024008571 A MX2024008571 A MX 2024008571A MX 2024008571 A MX2024008571 A MX 2024008571A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- beta
- pluripotent stem
- modified
- modifications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298214P | 2022-01-10 | 2022-01-10 | |
| US202263320691P | 2022-03-16 | 2022-03-16 | |
| US202263322208P | 2022-03-21 | 2022-03-21 | |
| US202263352605P | 2022-06-15 | 2022-06-15 | |
| US202263353534P | 2022-06-17 | 2022-06-17 | |
| PCT/US2023/060341 WO2023133568A2 (en) | 2022-01-10 | 2023-01-09 | Hypoimmune beta cells differentiated from pluripotent stem cells and related uses and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008571A true MX2024008571A (es) | 2024-09-19 |
Family
ID=87074351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008571A MX2024008571A (es) | 2022-01-10 | 2023-01-09 | Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250223564A1 (https=) |
| EP (1) | EP4463171A4 (https=) |
| JP (1) | JP2025504392A (https=) |
| KR (1) | KR20240142624A (https=) |
| AU (1) | AU2023204829A1 (https=) |
| CA (1) | CA3246902A1 (https=) |
| IL (1) | IL314029A (https=) |
| MX (1) | MX2024008571A (https=) |
| WO (1) | WO2023133568A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024264889A1 (en) * | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| US20250057880A1 (en) * | 2023-07-28 | 2025-02-20 | Vertex Pharmaceuticals Incorporated | Cell therapy for diabetes |
| CN116732099B (zh) * | 2023-08-07 | 2023-11-24 | 北赛泓升(北京)生物科技有限公司 | 一种干细胞多重CRISPR/Cas基因组编辑方法 |
| WO2025117331A1 (en) | 2023-12-01 | 2025-06-05 | Eli Lilly And Company | Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344758B1 (en) * | 2015-09-01 | 2021-09-29 | Ncardia B.V. | An in vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population |
| JP2020505025A (ja) * | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
| CA3109078A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Cells differentiated from immunoengineered pluripotent cells |
| WO2020018620A1 (en) * | 2018-07-17 | 2020-01-23 | The Regents Of The University Of California | Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells |
| AU2021262766A1 (en) * | 2020-04-27 | 2022-11-24 | Sana Biotechnology, Inc. | Repeat dosing of hypoimmunogenic cells |
-
2023
- 2023-01-09 KR KR1020247026729A patent/KR20240142624A/ko active Pending
- 2023-01-09 CA CA3246902A patent/CA3246902A1/en active Pending
- 2023-01-09 EP EP23737829.4A patent/EP4463171A4/en active Pending
- 2023-01-09 MX MX2024008571A patent/MX2024008571A/es unknown
- 2023-01-09 IL IL314029A patent/IL314029A/en unknown
- 2023-01-09 AU AU2023204829A patent/AU2023204829A1/en active Pending
- 2023-01-09 WO PCT/US2023/060341 patent/WO2023133568A2/en not_active Ceased
- 2023-01-09 JP JP2024541154A patent/JP2025504392A/ja active Pending
- 2023-01-09 US US18/727,670 patent/US20250223564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250223564A1 (en) | 2025-07-10 |
| EP4463171A2 (en) | 2024-11-20 |
| WO2023133568A2 (en) | 2023-07-13 |
| WO2023133568A3 (en) | 2023-08-10 |
| AU2023204829A1 (en) | 2024-07-11 |
| KR20240142624A (ko) | 2024-09-30 |
| JP2025504392A (ja) | 2025-02-12 |
| EP4463171A4 (en) | 2026-03-18 |
| CA3246902A1 (en) | 2023-07-13 |
| IL314029A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024008571A (es) | Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados. | |
| MX2022008783A (es) | Cambios de seguridad para la regulación de la expresión génica. | |
| WO2022146891A3 (en) | Methods and compositions for modulating car-t activity | |
| MX2021009842A (es) | Células madre de donantes universales y métodos relacionados. | |
| Boyd et al. | Concise review: Immune recognition of induced pluripotent stem cells | |
| MX2024001443A (es) | Sistemas inducibles para alterar la expresión génica en células hipoinmunógenas. | |
| CO2021004223A2 (es) | Células donantes universales | |
| MX2023007466A (es) | Composiciones y métodos para reducir los hla-a en una célula. | |
| MX2023006878A (es) | Composiciones y métodos para reducir el mhc de clase ii en una célula. | |
| GB2434157A (en) | Platelets from stem cells | |
| SA522431817B1 (ar) | خلايا مانحة شاملة | |
| CY1122390T1 (el) | Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων | |
| WO2005116192A3 (en) | Genetically engineered cells for therapeutic applications | |
| ZA200500682B (en) | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith | |
| WO2000006705A3 (de) | Genetisch modifizierte cd34-negative, adhärent wachsende stammzellen und deren verwendung in der gentherapie | |
| MX2023014017A (es) | Celulas hipoinmunogenas que comprenden proteina variante del antigeno leucocitario humano e (hla-e) o una proteina variante del antigeno leucocitario humano g (hla-g) modificados geneticamente. | |
| WO2022115641A3 (en) | Antigen specific t cells and methods of making and using same | |
| PH12022550543A1 (en) | Universal donor cells | |
| BR0211491A (pt) | Geração de células dendrìticas totalmente madura e estáveis de produtos de leucafereses para aplicações clìnicas | |
| MX2023008055A (es) | Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados. | |
| WO2023280307A9 (en) | Mutant il-15 compositions and methods thereof | |
| MX2024007528A (es) | Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados. | |
| MX2024015534A (es) | Composiciones y metodos para reducir mhc de clase i en una celula | |
| WO2023287827A3 (en) | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells | |
| Gołąb et al. | Impact of culture medium on CD4+ CD25highCD127lo/neg Treg expansion for the purpose of clinical application |